Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study

Shimose, Shigeo and Iwamoto, Hideki and Tanaka, Masatoshi and Niizeki, Takashi and Shirono, Tomotake and Noda, Yu and Kamachi, Naoki and Okamura, Shusuke and Nakano, Masahito and Suga, Hideya and Yamaguchi, Taizo and Kawaguchi, Takumi and Kuromatsu, Ryoko and Noguchi, Kazunori and Koga, Hironori and Torimura, Takuji (2021) Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers, 13 (1). p. 160. ISSN 2072-6694

[thumbnail of cancers-13-00160-v2.pdf] Text
cancers-13-00160-v2.pdf - Published Version

Download (1MB)

Abstract

We aimed to evaluate the impact of alternating lenvatinib (LEN) and trans-arterial therapy (AT) in patients with intermediate-stage hepatocellular carcinoma (HCC) after propensity score matching (PSM). This retrospective study enrolled 113 patients with intermediate-stage HCC treated LEN. Patients were classified into the AT (n = 41) or non-AT group (n = 72) according to the post LEN treatment. Overall survival (OS) was calculated using the Kaplan–Meier method and analyzed using a log-rank test after PSM. Factors associated with AT were evaluated using a decision tree analysis. After PSM, there were no significant differences in age, sex, etiology, or albumin-bilirubin (ALBI) score/grade between groups. The survival rate of the AT group was significantly higher than that of the non-AT group (median survival time; not reached vs. 16.3 months, P = 0.01). Independent factors associated with OS were AT and ALBI grade 1 in the Cox regression analysis. In the decision tree analysis, age and ALBI were the first and second splitting variables for AT. In this study, we show that AT may improve prognosis in patients with intermediate-stage HCC. Moreover, alternating LEN and trans-arterial therapy may be recommended for patients below 70 years of age with ALBI grade 1.

Item Type: Article
Subjects: Science Repository > Medical Science
Depositing User: Managing Editor
Date Deposited: 22 Nov 2022 05:32
Last Modified: 23 Aug 2023 04:29
URI: http://research.manuscritpub.com/id/eprint/254

Actions (login required)

View Item
View Item